Platinum-Sensitive Fallopian Tube Carcinoma

subtype

Identifier: CI-CAN-00008266
Entity page: /cancer/platinum-sensitive-fallopian-tube-carcinoma ↗
Edges: 14

Neighbours: 10 drugs4 trials
Drawn: 14 of 14 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Platinum-Sensitive Fallopian Tube Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived10 of 10
→ investigated in trials for	Aldesleukinother 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Platinum-Sensitive Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Anti-VEGF Monoclonal Antibody 1 trials (1 active) · roll-up of the cancer and its descendants

Platinum-Sensitive Fallopian Tube Carcinoma studied in …STUDIED_INderived4 of 4
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 4 trials mapped (2 active)	—	—	Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 4 trials mapped (2 active)	—	—	Platinum-Sensitive Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03691376Phase 1 · terminated Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 4 trials mapped (2 active)	—	—	Platinum-Sensitive Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05002868Phase 1 · completed Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors · condition mapped ONTOLOGY_EXACT · 4 trials mapped (2 active)	—	—	Platinum-Sensitive Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →

Platinum-Sensitive Fallopian Tube Carcinoma studied in …STUDIED_INderived4 of 4

→ studied in

NCT07504588Phase 2 · recruiting

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 4 trials mapped (2 active)

—

Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT04034927Phase 2 · active not recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 4 trials mapped (2 active)

—

Platinum-Sensitive Fallopian Tube Carcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT03691376Phase 1 · terminated

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 4 trials mapped (2 active)

—

Platinum-Sensitive Fallopian Tube Carcinoma

Observed

clinicaltrials

graph →

→ studied in

NCT05002868Phase 1 · completed

Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors · condition mapped ONTOLOGY_EXACT · 4 trials mapped (2 active)

—

Platinum-Sensitive Fallopian Tube Carcinoma

Observed

clinicaltrials

graph →

Radial view

Every edge, grouped by relationship

Strongest chains